Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody®

- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave...

Related Keywords

United States ,Japan ,Australia ,Florida ,Orlando ,Singapore ,China ,Suzhou ,Jiangsu , ,Twitter ,European Union ,Linkedin ,Adagene Inc ,Dynamic Precision Library ,Nasdaq ,Safety Profile Reinforced ,Clinical Responses ,Tumor Shrinkage ,Prolonged Stable Disease Supports ,Dose Expansion Ongoing ,Tumor Potential Shown ,Nasdaq Adag ,Dagene Inc ,